Big Pharma has a hiring “tell”—and it’s not in the job postings.
It’s in the patent cliff.
When blockbuster exclusivity sunsets, the industry doesn’t just feel it in revenue statements. It shows up in headcount decisions, org charts, and the quiet real…

Biosimilar sourcing is no longer a procurement problem—it’s an IP strategy problem.
If you’re planning a switch from an originator to a biosimilar, the biggest risk usually isn’t clinical. It’s timing.
Because in biosimilars, “available” doesn’t always…

Old Drugs. New Prices. Same Pills. Why Pharma Can Still Charge a Premium.
There’s a quiet shift happening across healthcare—one that rarely makes headlines until patients feel it in their monthly bills.
A growing number of “repurposed” medicines—older …

Pharma is hiring—quietly, strategically, and often through the back door of patent data.
Most recruiters still treat patents as a compliance artifact: something to file, monitor, or litigate. But in the hands of the right talent team, patent citations …

Old Drugs. New Prices. The Pharma Playbook for “Repurposed” Premiums.
There’s a quiet shift happening across healthcare—one that rarely makes headlines until patients feel it in their monthly bills.
A growing number of medicines that were once consider…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “third wheel” rule is more than a legal quirk—it’s a signal flare for the next decade of drug supply.
If you’ve been watching Russia’s push to secure medicines, you’ve probably heard the phrase “third wheel rule.” But the real story isn’t the …

Europe’s patent system is supposed to deliver clarity—yet for patients, payers, and generic manufacturers, “clarity” can look a lot like delay.
In a recent analysis by DrugPatentWatch, the spotlight lands on a strategy that’s become increasingly common…

Pharma patent litigation used to be a “cost of doing business.” Now it’s a board-level risk.
Drug patent watch recently highlighted a striking shift: litigation costs that once ran as high as $50M can be driven down to $5M—not by hoping cases settle, b…

PBMs don’t just “manage formularies.” They shape the economics of every branded drug in the U.S.—often long before a patient ever sees a prescription.
And if you’re a pharma executive, payer strategy isn’t a side project anymore. It’s the difference be…